Got to News overview News

Welcome to the sixth issue of our e-newsletter

News Newsletter

We are writing to you with the latest news from the RADAR-CNS (Remote Assessment of Disease and Relapse – Central Nervous System) programme.

Since we were last in touch in January 2020, the worldwide COVID-19 pandemic has affected all parts of our lives, including RADAR-CNS. Our project management team continues to monitor the situation closely and is in contact with our funder, the Innovative Medicines Initiative (IMI).  Our website contains the most up-to-date information on how our clinical teams are adapting to the changing situation. The valued contributions from our participants are more important than ever to help us gain a better understanding and insight into the lives of people living with epilepsy, MS and depression.

We have asked participants to continue engaging with RADAR-CNS as best they can during this unsettling period and we have been hugely impressed by how well participants have been able to stay in touch. In this issue we share interviews with some of our researchers in Spain, Belgium and England on how they’ve adapted to work and life during the pandemic.

In February we were able to attend The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium’s public meeting ‘Remote Digital Monitoring for Medical Product Development Workshop’ in in Bethesda, Maryland, US. We presented a case study on RADAR – MDD. Since then many face-to-face events, meetings and conferences have been cancelled, postponed or held virtually. Our annual meeting will also be held virtually this year due to the pandemic.

With the team across the consortium publishing more papers on our findings we want to be able to share these results with the public, our newsletter subscribers, and our colleagues. Therefore, we are starting a new RADAR-CNS webinar series where our research team will present our latest findings. We will email with further details of the first webinar in due course.

We have now finished recruitment for both the MS-Disability study with the target of 400 participants reached and the major depressive disorder study with more than 600 participants. A huge thanks go to our colleagues from the MDD study for their continued dedication to achieving these goals.

You will receive our next newsletter in January 2021. In the meantime, you can find regular news updates on our project website -, as well as our latest research papers and publications.

Until next time!

Matthew Hotopf, King's College London
Vaibhav Narayan, Janssen Pharmaceutica NV
RADAR-CNS Project Co-Leads

Share this page…